RedHill Biopharma Ltd (RDHL)

[H2R]

Two positive RDHL articles on SA today:

http://seekingalpha.com/article/4056586-redhill-biopharma-multiple-drugs-advanced-phase-iii-development-provide-substantial-upside

http://seekingalpha.com/article/4056540-redhill-keeps-speciality-dream-alive

I like this excerpt best, as it summarizes clearly a Bull thesis :

[...] [RDHL] had a market cap of only $175 million with little or no debt and approximately $70 million in cash (as of January 12, 2017).

[...]

For a small company, RedHill has a remarkable number of advanced stage drugs in its pipeline with very significant potential markets; as well 2017 is an important year for RedHill with a number of upcoming catalysts.

Of its 7 drugs in clinical development, RedHill has three potential blockbuster gastrointestinal drugs in three ongoing U.S. Phase III clinical trial programs:

(1) RHB-104 (Crohn's): First Phase III study ongoing;

(2) RHB-105 (H. pylori): First Phase III study successfully met its primary endpoint with high statistical significance (p<0.001), confirmatory Phase III planned to be initiated in Q2/2017; and

(3) BEKINDA®* (RHB-102) (gastroenteritis and gastritis): Phase III study ongoing.

As well, RedHill has multiple ongoing additional Phase II programs.